Background {#Sec1}
==========

Cardiovascular disease (CVD) and CVD risk conditions, such as hypertension, type 2 diabetes mellitus (T2DM), and chronic kidney disease (CKD), are the leading cause of global morbidity and mortality \[[@CR1]\]. Increasingly larger proportions of the global population are exposed to risk of non-communicable disease (NCD), such as urbanization, tobacco use, and sedentary behavior \[[@CR2]\]. The growing prevalence of these conditions is particularly troublesome in low- and middle-income countries (LMICs), where age-specific rates for NCD mortality are nearly twice as high as in high-income countries \[[@CR3]\], and treatment can be very costly \[[@CR4]\]. There is evidence that health systems in these settings are already strained by the dual burden of infectious and chronic disease, especially in resource-limited settings \[[@CR5]\]. Many people suffering from CVD in LMICs remain untreated, or their conditions are poorly managed, due to lack of access to primary health care and high costs \[[@CR6]\].

Efforts to improve prevention and management of NCDs in LMICs are increasing. Mortality reduction targets, such as the World Heart Federation's 25 × 25 and the Lancet's 40 × 30, are unprecedented in putting NCDs on the international agenda \[[@CR7], [@CR8]\]. The resources required in order to meet these targets in any given LMIC are less clear. Economic evaluations are especially important for settings that do not yet have policies or the infrastructure in place to address these emerging issues \[[@CR9]\]. Unfortunately, financial and economic cost estimates of these interventions in LMICs are limited. In order to raise awareness of the economic costs of CVD and to support increased allocation of resources for addressing CVD and risk conditions, accurate cost data are needed by donors, ministries of health and economic modelers.

Recent reviews of household burden or cost-effectiveness of CVD interventions in LMICs have been published \[[@CR6], [@CR10]--[@CR13]\]; however, there are no recent reviews, to our knowledge, of provider-incurred costs of interventions for CVD and risk conditions. We therefore reviewed literature on the provider-incurred costs for the treatment of cardiovascular and related risk conditions in health system settings of LMICs. Specifically, we consider diabetes, chronic kidney disease, hypertension and hyperlipidemia, stroke, ischemic heart disease, and non-ischemic heart diseases. We chose these conditions because of their interrelated risk factors and the large overlap in clinical resources that are required to management them. We will refer to the entire grouping as "CVRD" (cardiovascular and related diseases) throughout the remainder of the paper.

Our primary objective was to present the level and variability in direct medical or programmatic costs for treating CVRD in LMICs. Our secondary objective was to identify gaps in knowledge and suggest future economic research needs to support policy development, resource allocation, and decision-making.

Methods {#Sec2}
=======

Search strategy and article retrieval {#Sec3}
-------------------------------------

We conducted our review according to the PRISMA guidelines \[[@CR14]\]. We searched the following databases: Medline, EMBASE, NHS-EED, HEED and EconLit. We adapted the search terms specifically to each database, using 1) terms related to cardiovascular diseases and risk conditions plus 2) terms for LMICs and regions plus 3) terms denoting economic evaluation. Additional file [1](#MOESM1){ref-type="media"} details the full strategy. We limited our results to articles published on or after January 1^st^, 2000 until approximately July 1^st^, 2014. We screened eligible titles and abstracts to determine which articles would be included for final review. Two independent reviewers reviewed the full text articles. In addition, we examined the references of the included articles and prior reviews for potentially relevant studies. Broadly, the following criteria were used to determine inclusion:Included an economic evaluationIncluded evaluation of at least one low- or middle-income country (as defined by the World Bank)Referred to our previously standardized list of cardiovascular or related-related conditionsMade available in EnglishPublished on or after January 2000.

We used both the Drummond Checklist and Mogyorosy and Smith's 2012 literature review for guidance in creating the following guidelines regarding quality and inclusion \[[@CR15], [@CR16]\]:The study must have conducted at least one type of economic evaluation, including cost analysis, cost-effective analysis, or cost-utility analysis, with clearly presented unit cost data.We did not consider costs with health outcomes as a denominator, such as disability-adjusted life years (DALYs), quality adjusted life years (QALYs), or life-years saved (LYS).The study must have utilized either original unit cost data regarding a CVRD intervention delivered in a health systems setting, or unit costs from a credible and known source, such as WHO-CHOICE. We did not consider population-level interventions or policy costs.The study must have presented direct intervention costs (medical or programmatic) from the provider perspective, regardless of payer or indirect costs. Studies that considered multiple perspectives were only considered if they clearly delineated provider costs. Provider costs were defined as those delivering the services, such as those incurred by health systems, hospitals or clinics, governmental bodies, funders, or programs.The study had to meet certain quality standards, which includes having a description of the intervention and analysis, detailing the time and location of data collection, and clearly stating the year and currency of presented costs.

To inform the organization and synthesis of the literature across conditions and interventions, we created a conceptual framework of the clinical and public health considerations in CVD treatment (Fig. [1](#Fig1){ref-type="fig"}). There are several points at which one can intervene on cardiovascular risk factors, risk conditions, and CVDs themselves, both within and outside of the health system. This review examines only the costs that exist within the health sector, and health facilities specifically, but across the spectrum of cardiovascular risk conditions and diseases themselves.Fig. 1CVRD Conceptual Framework. This framework informed our inclusion criteria and subsequent data extraction and organization

Data extraction {#Sec4}
---------------

For each eligible study we entered the following information into an electronic database: condition(s), country or region, target population, type of treatment or intervention, and level of care. We also noted study methods, such as sample size and strategy, exchange rate, discount rate, sensitivity analysis, and cost categories. The total treatment or intervention costs, defined as the total cost per patient, were extracted in their original currency and year. For acute events, we used the total cost per patient as presented. For recurring costs, such as hemodialysis treatments or ongoing hypertension management, we calculated the cost per treatment or per year. Differences in inpatient and outpatient costs were noted where reported and applicable. Of note, most of the included studies reported multiple costs, particularly if they discussed more than one CVRD intervention or more than one geographic setting.

We converted all costs to US Dollars (2012), the currency and year in which we present all costs in this paper. When possible, we extracted the data in local currency units (LCUs), inflated it to 2012 rates using the World Bank consumer price indices, and converted it to 2012 US Dollars via World Bank rates. When costs were presented for regions, we used the largest LMIC country in the region as a proxy. For data presented in international dollars, we converted it back into LCUs using World Bank Purchasing Power Parity, then we followed our standard processes. Once the data were in a common currency, we grouped similar interventions and qualitatively compared the magnitudes and variability of total and input costs. We combined data into the two overarching groups to reflect our aforementioned framework: management of CVD risk conditions and treatment of acute and chronic CVDs. The former group included hypertension, hyperlipidemia, CKD, T2DM, and generic CVD prevention. The latter group focused specifically on ischemic heart disease, non-ischemic heart diseases, stroke, heart failure, T2DM sequelae (specifically, microvascular complications such as foot ulcers and retinopathy), and end-stage renal disease (ESRD), which is due predominately to poorly controlled hypertension and T2DM.

Results {#Sec5}
=======

The results of the systematic search process can be found in Fig. [2](#Fig2){ref-type="fig"}. 60 studies met our final inclusion criteria, presenting approximately 143 unit costs reported in Table [1](#Tab1){ref-type="table"}. An additional 121 studies were reviewed at the full text stage but were excluded on the basis of our inclusion criteria or for methodological reasons, i.e., they did not meet the criteria in our quality checklist.Fig. 2Article Selection Flow Chart (PRISMA STANDARDS). Flow diagram for the selection of published articles evaluating the costs of providing preventive care or treatment for cardiovascular disease, diabetes, and chronic kidney disease in low- and middle-income countriesTable 1Unit cost data for the treatment of cardiovascular risk conditions (USD 2012)Sub-Condition (If Applicable)Intervention or TreatmentCountryCost Presented in PaperUnitCurrency (Year)Cost in USD (2012)UnitManagement of cardiovascular risk conditionsHypertensionHypertension Drug Treatment \[[@CR34]\]Nigeria300.00--2,100.00Per monthNigeria (2010)\$2.38--\$16.66Per patient per yearPharmacological high blood pressure and cholesterol treatment \[[@CR35]\]Tanzania1.57--54.28Per yearUS (2005)\$2.21--\$76.29Per patient per yearPharmacological high blood pressure treatment \[[@CR33]\]Argentina49.72Per patient per yearUS (2007)\$52.24Per patient per yearCommunity Hypertension Control Program: Home Health Education and General Practitioner \[[@CR36]\]Pakistan3.99Per patient per yearUS (2007)\$4.96Per patient per yearCommunity Hypertension Control Program: Home Health Education \[[@CR36]\]Pakistan3.34Per patient per yearUS (2007)\$4.15Per patient per yearCommunity Hypertension Control Program: General Practitioner \[[@CR36]\]Pakistan0.65Per patient per yearUS (2007)\$0.81Per patient per yearCommunity Hypertension Reduction Program (1-year) \[[@CR37]\]China7.17Per patient per yearUS (2009)\$8.67Per patient per yearGuideline-Oriented Training Program for Hypertension Control in Community Health Centers \[[@CR38]\]China79.30Per yearUS (2002)\$138.96Per yearHypertension Outpatient Treatment \[[@CR32]\]South Africa86.00Per patient per yearUS (2001)\$169.28Per patient per yearHypertension Outpatient Treatment \[[@CR39]\]China487.30Per patient per yearUS (2010)\$565.54Per patient per yearHypertension Outpatient Treatment at Urban Health Clinic \[[@CR40]\]Thailand916.54Per patient per yearThailand (1999)\$41.42Per patient per yearHypertension Outpatient Treatment \[[@CR41]\]China96.90Per outpatient visitChina (2003)\$20.28Per outpatient visitHypertension Outpatient Treatment and Medications \[[@CR42]\]Tanzania38.00Per patient per yearUS (2012)\$38.00Per patient per yearHypertension Inpatient Visit \[[@CR41]\]China3,904.00Per inpatient stayChina (2003)\$817.10Per inpatient stayHypertensive Emergency Treatment Cost (Inpatient and Outpatient) \[[@CR43]\]Congo, Rep.159,600.00Per patientCongo, Rep. (2006)\$400.90Per patientHyperlipidemiaScreening for dyslipidemia among healthy 35--39 year olds \[[@CR44]\]Thailand127.22Per patient screenedThailand (2008)\$4.48Per patient screenedScreening for dyslipidemia among healthy 35--60 year olds \[[@CR45]\]Thailand1,043.60Per case detectedThailand (2008)\$36.77Per case detectedPharmacological high cholesterol treatment \[[@CR33]\]Argentina118.79Per patient per yearUS (2007)\$124.81Per patient per yearHome visit by Health Care Professional \[[@CR40]\]Thailand574.86Per visitThailand (1999)\$25.98Per visitChronic Kidney DiseaseAmlodipine (Anti-hypertensive Drug Therapy for Patients with Diabetes, Hypertension, and Nephropathy) \[[@CR29]\]China2,013.00Per yearUS (2004)\$3,356.78Per patient per yearIrbesartan (Anti-hypertensive Drug Therapy for Patients with Diabetes, Hypertension, and Nephropathy) \[[@CR29]\]China1,660.00Per yearUS (2004)\$2,768.13Per patient per yearAmlodipine (Anti-hypertensive Drug Therapy for Patients with Diabetes, Hypertension, and Nephropathy) \[[@CR29]\]Malaysia332.00Per yearUS (2004)\$503.07Per patient per yearIrbesartan (Anti-hypertensive Drug Therapy for Patients with Diabetes, Hypertension, and Nephropathy) \[[@CR29]\]Malaysia258.00Per yearUS (2004)\$390.94Per patient per yearAmlodipine (Anti-hypertensive Drug Therapy for Patients with Diabetes, Hypertension, and Nephropathy) \[[@CR29]\]Thailand779.00Per yearUS (2004)\$1,302.06Per patient per yearIrbesartan (Anti-hypertensive Drug Therapy for Patients with Diabetes, Hypertension, and Nephropathy) \[[@CR29]\]Thailand1,340.00Per yearUS (2004)\$2,239.75Per patient per yearType 2 Diabetes MellitusScreening using fasting capillary blood glucose \[[@CR46]\]China10.00Per testChina (2009)\$1.77Per patientScreening using Diabetes Risk Score \[[@CR46]\]China5.00Per testChina (2009)\$0.89Per patientScreening for diabetes in a community health clinic \[[@CR47]\]China3.00Per patientUS (2007)\$4.25Per patientTertiary Hospital Diagnostic Test \[[@CR46]\]China95.00Per testChina (2009)\$16.82Per patientPrimary Care - Behavior management program to prevent diabetes \[[@CR48]\]India54.67Per patient per yearUS (2006)\$78.93Per patient per yearPrimary Care - Metformin regimen to prevent diabetes \[[@CR48]\]India53.00Per patient per yearUS (2006)\$76.53Per patient per yearPrimary Care - Behavior management program with Metformin regime to prevent diabetes \[[@CR48]\]India69.67Per patient per yearUS (2006)\$100.59Per patient per yearMean total annual direct medical cost (without complication) \[[@CR49]\]China5,313.20Per yearChina (2007)\$989.16Per patient per yearMean total annual direct medical cost (with complication) \[[@CR49]\]China13,320.10Per yearChina (2007)\$2,479.82Per patient per yearAnnual treatment costs (inpatient and outpatient costs) \[[@CR50]\]Thailand6,331.00Per patient per yearThailand (2001)\$277.14Per patient per yearAnnual treatment costs (inpatient and outpatient costs) \[[@CR51]\]Nigeria47,924.36Per patient per yearNigeria (2010)\$380.14Per patient per yearAnnual Diabetes Treatment in Community Clinic (Including Inpatient and Outpatient Visits) \[[@CR52]\]Brazil1,319.15Per yearUS (2010)\$1,335.52Per patient per yearAnnual treatment costs (inpatient and outpatient costs) \[[@CR53]\]India3,006.00Per patient per yearIndia (2012)\$56.25Per patient per yearUrban Health Center providing primary community care \[[@CR40]\]Thailand1,408.59Per patient per yearThailand (1999)\$63.66Per outpatient visitInpatient stay w/o hypertension (Average 7 Days LOS) \[[@CR54]\]India18,650.00Per inpatient stayIndia (2007)\$558.77Per inpatient stayInpatient Stay w/hypertension (Average 5 Days LOS) \[[@CR54]\]India21,000.00Per inpatient stayIndia (2007)\$629.18Per inpatient stayInpatient stay w/o hypertension (Average 7 Days LOS) \[[@CR54]\]India28,000.00Per two yearsIndia (2007)\$419.45Per patient per yearInpatient Stay w/hypertension (Average 5 Days LOS) \[[@CR54]\]India38,000.00Per two yearsIndia (2007)\$569.25Per patient per yearInpatient Treatment: without complication (Average 9.8 Days LOS) \[[@CR55]\]China6,903.93Per patientChina (2006)\$1,346.37Per inpatient stayInpatient Treatment: with chronic complications (Average 9.8 Days LOS) \[[@CR55]\]China7,193.15Per patientChina (2006)\$1,402.77Per inpatient stayInpatient/Hospital Admission \[[@CR56]\]Thailand95.99Per dayUS (2008)\$112.65Per dayInpatient Treatment in Community Clinic (No LOS Stated) \[[@CR52]\]Brazil26.32Per yearUS (2010)\$26.65Per patient per yearOutpatient Care \[[@CR56]\]Thailand3.94Per outpatient visitUS (2008)\$4.63Per outpatient visitOutpatient Care in Community Clinic \[[@CR52]\]Brazil1,216.33Per yearUS (2010)\$1,231.43Per patient per yearOutpatient treatment for patient without complications \[[@CR57]\]India4,493.00Per yearIndia (2009)\$112.05Per inpatient stayOutpatient Treatment \[[@CR58]\]Nepal16.95Per outpatient visitUS (2010)\$17.45Per outpatient visitOutpatient Treatment \[[@CR58]\]Nepal130.52Per yearUS (2010)\$134.38Per patient per yearOutpatient Treatment \[[@CR59]\]Brazil1,014.00Per patient per yearUS (2007)\$1,322.64Per patient per yearOutpatient Treatment \[[@CR60]\]Pakistan1,468.90Per outpatient visitPakistan (2006)\$32.34Per outpatient visitOutpatient Treatment \[[@CR41]\]China163.80Per outpatient visitChina (2003)\$34.28Per outpatient visitOther clinical management of CVD risk conditionsGeneric primary preventionModified poly-pill strategy \[[@CR33]\]Argentina103.46Per patient per yearUS (2007)\$108.70Per patient per yearGeneral Outpatient Visit \[[@CR40]\]Thailand67.82Per outpatient visitThailand (1999)\$3.07Per outpatient visitBupropion treatment HCW counseling for tobacco cessation \[[@CR33]\]Argentina117.15Per patient per yearUS (2007)\$123.09Per patient per yearRheumatic FeverPrevention of Rheumatic Fever (throat culture)India1,088.56Per patientIndia (2007)\$32.61Per patientPost rheumatic fever prophylaxis \[[@CR61]\]India879.35Per patientIndia (2007)\$26.35Per patientInpatient Treatment for acute rheumatic fever \[[@CR62]\]South Africa2,958.00Per patientUS (2010)\$2,927.41Per patientEchocardiographic screening for rheumatic heart disease in schoolchildren \[[@CR63]\]Fiji2.07Per patient screenedUS (2008)\$2.27Per patient screened

The number of published articles for CVD costs in LMICs has increased dramatically since 2000, as seen in Fig. [3](#Fig3){ref-type="fig"}. In fact, we identified only five articles in the years 2000--2006, increasing to 16 articles published in 2013, the last complete year of our review. Most of the cost data occurred either in urban areas or at the national level of middle income countries, with only four studies considering low-income countries. The sample is mainly from Asian countries (34 articles), dominated by studies from India (8 articles) and China (12 articles). Almost a quarter of the cost data came from China; India contributed the next highest frequency of cost data (14 %). One-third of our cost data concerned diabetes, which was a considerably higher proportion than any other condition, and two-thirds of those diabetes costs were from Asian-based studies.Fig. 3Articles Published by Year & Region. Figure shows the number of articles identified by our study disaggregated by the year in which they were published and the region (as defined by the World Bank) for which they provide data. Studies providing data for more than one region were categorized as "multiple"

We obtained cost data from a variety of economic evaluations. Almost two-thirds of the articles (*n* = 37) were cost analyses, meaning they only collected and presented data on costs, not health outcomes. Thirty studies determined the total costs of interventions by reviewing hospital records while 29 studies used an ingredients approach, taking the sum cost of activities and resources used to find the total costs. Only one study used a questionnaire to collect data. Of the 60 studies, over half converted their costs in US Dollars or the hypothetical currency "International Dollars" for presentation (32 articles). Although it is difficult to measure the quality of a study objectively, economic evaluation guidelines recommend discounting future costs and conducting sensitivity analyses when assumptions are made. We noted that approximately one-third of the 60 studies conducted sensitivity analysis, and one-fourth used discounting in their methods; 11 articles used both.

Management of cardiovascular risk conditions {#Sec6}
--------------------------------------------

Our review identified 60 cost estimates from 31 articles for clinical management of CVD risk conditions such as hypertension, hyperlipidemia, chronic kidney disease and T2DM). There were also brief mentions of pharmacological tobacco cessation measures, rheumatic fever and generic CVD prevention strategies such as polypill use. More than three-quarters of this data came from Asian countries, and more than half from China, India or Thailand.

We found 14 unit costs for hypertension management in LMICs, with drug therapy ranging from \$2.21--\$76.29. Using general practitioners in community programs cost only \$0.81--\$8.67 per patient per year, compared to annual outpatient costs to manage hypertension, which ranged from \$38.00 to \$565.54 per patient. Only three studies mentioned the costs of managing dyslipidemia, which were similar to managing hypertension. One study looked at the costs of managing chronic kidney disease across China, Malaysia and Thailand, with China being more expensive than Malaysia by a scale of six to eight. We identified 30 unit costs for managing diabetes. Two studies produced four costs on diagnosing diabetes, the most expensive of which were based in tertiary hospitals. Seven studies presented ten annual per patient costs of managing diabetes in a clinical setting, which ranged from \$56.25 in India to \$2,479.82 in China; the costs were higher in cases with complications and sequelae. Nine studies also presented 16 costs on inpatient and outpatient treatment for diabetes. Inpatient stays per bed-day ranged from \$59.92--\$143.14 with an average length of stay of around 7 days. An outpatient visit ranged from \$4.63--\$34.28, and we also found a ten-fold variation in yearly outpatient costs.

Treatment and management of acute and chronic cardiovascular conditions {#Sec7}
-----------------------------------------------------------------------

Our review also identified 83 cost estimates from 34 studies regarding the treatment of ischemic heart disease (IHD), stroke, heart failure, non-ischemic heart diseases, T2DM sequelae, and end-stage renal disease (ESRD).

Treatment of IHD typically consists of diagnostic procedures, surgical or other advanced medical procedures, and post-operative and long-term outpatient care. We found 8 articles analyzing IHD treatment with a total of 18 unit costs. An inpatient visit averaged \$8,800, with a range from \$455 to \$22,500. The highest inpatient costs were associated with longer hospitalization periods, more severe conditions, and surgical interventions. The costs of surgical procedures, including catheter-based procedures (stenting and angioplasty) or coronary artery bypass surgery (CABG), ranged from \$4,000--\$22,000 per patient per procedure depending on the diagnostics, the complexity of the procedure, and whether medical therapy and recovery costs were included in the total cost estimates.

Our search returned 15 articles and 24 unit costs for both ischemic stroke (IS) and hemorrhagic stroke (HS), though many studies did not specify the type of stroke. In most settings, IS is the more common of the two, is generally easier to treat, and has a lower case-fatality rate. Four articles compared the costs HS and IS treatment \[[@CR17]--[@CR20]\]. Hemorrhagic strokes were generally more severe, required longer hospital stays, and involved surgical or intensive care unit costs; HS treatment costs were between 0 % and 50 % higher than IS treatment. The majority of articles provided the inpatient cost per stroke event, but did not distinguish the type of strokes. The average inpatient cost of a stroke was \$3,240, but this varied widely by geographic setting, technical resources used, and average length of stay.

Five studies reported costs of T2DM sequelae, namely, diabetic foot ulcers and retinopathy. Severity of these impairments and costs saved by screening drove the total costs of both, though in opposite directions \[[@CR21]--[@CR25]\]. For instance, screening for retinopathy was generally below \$30, while diabetic foot ulcers ranged from less than \$1 to over \$7,000 in the cases of infection and amputation.

Five studies reported costs of end-stage renal disease (ESRD), primarily long-term dialysis or renal transplantation. The cost of one session of hemodialysis for ESRD ranged \$79 to \$97 \[[@CR26]--[@CR28]\], while one study estimated average annual dialysis costs at \$61,000 in Southeast Asia \[[@CR29]\]. Kidney transplantation and post-operative care ran from \$5,000 to \$21,000 in the Sudan and Iran, respectively \[[@CR28], [@CR30]\].

Other types of CVD, such as heart failure, Chagas cardiomyopathy (CC), congenital heart disease, and rheumatic heart disease, are important contributors to the burden of NCDs in LMICs. However, we identified only a handful of studies on the cost of treating these conditions (Table [2](#Tab2){ref-type="table"}).Table 2Unit cost data for the treatment of cardiovascular disease and related condition (USD 2012)Treatment and Management of Acute/Chronic Cardiovascular and Related ConditionsIschemic Heart DiseaseOutpatient Visit (All direct medical costs) \[[@CR41]\]China245.40Per outpatient visitChina (2003)\$51.36Per outpatient visitCABG Procedure (Procedure and Medical Therapy) \[[@CR32]\]South Africa11,431.00Per patientUS (2001)\$22,500.46Per patientCABG Procedure (Procedure only, no medical therapy) \[[@CR64]\]China7,300.00Per patientUS (2007)\$10,339.01Per patientCABG Procedure (Procedure and Medical Therapy) \[[@CR65]\]Armenia3,368.19Per patientUS (2005)\$5,546.46Per patientCABG Procedure (Procedure and Medical Therapy) \[[@CR66]\]India8,055.00Per patientUS (2006)\$11,630.62Per patientStenting Procedure (Procedure only, no medical therapy) \[[@CR64]\]China10,000.00Per patientUS (2007)\$14,163.03Per patientCatheter-based revascularization Inpatient Treatment \[[@CR32]\]South Africa4,737.00Per patientUS (2001)\$9,324.18Per patientTotal operative procedures and examinations \[[@CR67]\]Brazil444.29Per patientBrazil (2001)\$455.47Per patientCoronary Angioplasty Diagnostic Strategy Including Therapy \[[@CR64]\]China3,568.00Per patientUS (2007)\$5,053.37Per patientComputed Tomography Angiography and Coronary Angioplasty Diagnostic Strategy \[[@CR64]\]China2,971.00Per patientUS (2007)\$4,207.84Per patientInpatient Visit (All direct medical costs) \[[@CR33]\]Argentina4,245.39Per patientUS (2007)\$4,460.54Per patientInpatient Visit (All direct medical costs) \[[@CR41]\]China11,008.20Per inpatient stayChina (2003)\$2,304.00Per inpatient stayInpatient Visit (All direct medical costs) \[[@CR68]\]Vietnam31,400,000.00Per inpatient stayVietnam (2005)\$3,257.15Per inpatient stayAverage Inpatient Treatment (All direct medical costs) \[[@CR32]\]South Africa5,636.00Per patientUS (2001)\$11,093.74Per patientAdditional cost if a CABG or valve replacement surgery results in a hospital-acquired infection \[[@CR66]\]India14,818.00Per patientUS (2006)\$21,395.72Per patientPost CHD with CABG (1st year) \[[@CR32]\]South Africa1,300.00Per yearUS (2001)\$2,558.88Per patient per yearPost CHD with CABG (subsequent years) \[[@CR32]\]South Africa600.00Per yearUS (2001)\$1,181.02Per patient per yearPost CHD without CABG (1st year) \[[@CR32]\]South Africa1,500.00Per yearUS (2001)\$2,952.56Per patient per yearPost CHD without CABG (subsequent years) \[[@CR32]\]South Africa840.00Per yearUS (2001)\$1,653.43Per patient per yearStrokeHemorrhagic StrokeInpatient Visit for Stroke Care (Average 11.8 Days LOS) \[[@CR17]\]Turkey1,348.00Per patientUS (2007)\$1,444.46Per patientInpatient Visit for Stroke Care (Average 12 Days LOS) \[[@CR18]\]Brazil1,831.00Per patientUS (2007)\$2,388.33Per patientTertiary Treatment and Follow-Up - Coiling (6 months) \[[@CR69]\]Pakistan304,800.00Per patientPakistan (2007)\$6,236.79Per patientTertiary Treatment and Follow-Up - Endovascular clipping (6 months) \[[@CR69]\]Pakistan187,620.00Per patientPakistan (2007)\$3,839.06Per patientIschemic StrokeInpatient Visit for Stroke Care (Average 10.4 Days LOS) \[[@CR17]\]Turkey956.00Per patientUS (2007)\$1,024.41Per patientInpatient Visit for Stroke Care (Average 13.3 Days LOS) \[[@CR18]\]Brazil1,645.00Per patientUS (2007)\$2,145.71Per patientInpatient Visit for Stroke Care (Average 18.5 Days LOS) \[[@CR70]\]China67.00Per patient per dayUS (2010)\$77.76Per patientInpatient Visit for Stroke Care (Average 18.5 Days LOS) \[[@CR70]\]China983.00Per patientUS (2010)\$1,140.84Per patientDiagnostics and preventative care for high-risk patients at a tertiary hospital \[[@CR71]\]China435.40Per patient per yearUS (2010)\$505.31Per patient per yearStroke (Non-Specified)Outpatient Visit \[[@CR41]\]China264.80Per outpatient visitChina (2003)\$55.42Per outpatient visitDirect Medical Costs for Managing a Stroke Patient in Year Following Stroke \[[@CR72]\]Nigeria62,217.00Per patientUS (2012)\$62,217.00Per patientDirect Medical and follow up (6-months) \[[@CR73]\]India57,381.00Per patientIndia (2011)\$1,173.80Per patientInpatient Visit for Stroke Care: Average across all wards (3--5 Days Ave. LOS) \[[@CR31]\]Pakistan1,179.00Per patientUS (2001)\$2,160.99Per patientInpatient Visit for Stroke Care: ICU (3--5 Days LOS) \[[@CR31]\]Pakistan3,583.50Per patientUS (2001)\$6,568.20Per patientInpatient Visit for Stroke Care: Private Ward (3--5 Days LOS) \[[@CR31]\]Pakistan1,248.00Per patientUS (2001)\$2,287.46Per patientInpatient Visit for Stroke Care: General Ward (3--5 Days LOS) \[[@CR31]\]Pakistan1,010.00Per patientUS (2001)\$1,851.23Per patientInpatient Visit for Stroke Care (LOS not stated) \[[@CR32]\]South Africa8,633.00Per patientUS (2001)\$16,992.95Per patientInpatient Visit for Stroke Care (LOS not stated) \[[@CR74]\]Tanzania138,000.00Per patientTanzania (2006)\$160.18Per patientInpatient Visit for Stroke Care (LOS not stated) \[[@CR33]\]Argentina3,455.48Per patientUS (2007)\$3,630.60Per patientInpatient Visit for Stroke Care (Up to 3 Days LOS) \[[@CR43]\]Congo, Rep.158,120.00Per patientCongo, Rep. (2006)\$397.19Per patientInpatient Visit for Stroke Care (LOS not stated) \[[@CR41]\]China7,953.10Per inpatient stayChina (2003)\$1,664.57Per inpatient stayInpatient Visit for Stroke Care: small hospital (Average 20 Days LOS) \[[@CR20]\]China7,119.00Per inpatient stayChina (2006)\$1,388.31Per inpatient stayInpatient Visit for Stroke Care: tertiary hospital (Average 20 Days LOS) \[[@CR20]\]China12,344.00Per inpatient stayChina (2006)\$2,407.26Per inpatient stayInpatient Visit for Stroke Care (Average 6.4 Days LOS) \[[@CR19]\]Malaysia3,696.40Per inpatient stayMalaysia (2005)\$1,431.57Per patient per admissionHeart FailureInpatient treatment for heart failure due to systolic or diastolic dysfunction with a Chagas' cardiomyopathy diagnosis \[[@CR75]\]Brazil467.00Per dayBrazil (2006)\$324.23Per dayOutpatient Treatment \[[@CR76]\]Brazil14.40Per outpatient visitBrazil (2002)\$13.61Per outpatient visitOutpatient Treatment plus medications \[[@CR76]\]Brazil557.28Per yearBrazil (2002)\$526.79Per patient per yearInpatient treatment for heart failure due to systolic or diastolic dysfunction with Non-Chagas' cardiomyopathy (other etiologies) \[[@CR75]\]Brazil308.00Per dayBrazil (2006)\$213.84Per dayInpatient Care (Up to 3 Days LOS) \[[@CR43]\]Congo, Rep.81,900.00Per patientCongo, Rep. (2006)\$205.73Per patientInpatient Care (Average 6.5 Days LOS) \[[@CR76]\]Brazil4,033.62Per inpatient stayBrazil (2002)\$3,812.90Per inpatient stayNeglected Heart DiseasesCongenital heart diseaseOperations and treatments, including pre and post-operative care \[[@CR67]\]Brazil1,428.05Per patientBrazil (2001)\$1,463.95Per patientRheumatic Heart DiseaseInpatient Treatment (Average 7 Days LOS) \[[@CR62]\]South Africa1,597.00Per patientUS (2010)\$1,580.49Per patientTertiary care (including inpatient care and surgery) \[[@CR61]\]India1,547.17Per patientIndia (2007)\$46.35Per patientType Two Diabetes MellitusDiabetic Foot UlcersTotal treatment \[[@CR21]\]Pakistan2,700.00Per patientPakistan (2005)64.15--\$1165.65Per patientTotal Treatment (healed) \[[@CR22]\]China1,673.00Per patient\$Int (2010)\$585.60Per patientTotal Treatment (trans-tibial amputation) \[[@CR22]\]China21,372.00Per patient\$Int (2010)\$7,480.87Per patientTotal Treatment (healed) \[[@CR22]\]India1,192.00Per patient\$Int (2010)\$85.51Per patientTotal Treatment (trans-tibial amputation) \[[@CR22]\]India19,599.00Per patient\$Int (2010)\$1,405.97Per patientTotal Treatment (healed) \[[@CR22]\]Tanzania102.00Per patient\$Int (2010)\$0.24Per patientTotal Treatment (trans-tibial amputation) \[[@CR22]\]Tanzania3,060.00Per patient\$Int (2010)\$7.30Per patientTotal Treatment \[[@CR23]\]Nigeria93,256.70Per patientNigeria (2003)\$1,618.55Per patientRetinopathyRetinopathy screening in a primary care setting \[[@CR24]\]South Africa22.00Per patientUS (2007)\$26.10Per patientLaser treatment in retinopathy confirmed cases \[[@CR24]\]South Africa144.00Per patientUS (2007)\$170.85Per patientScreening Retinal examination at a hospital \[[@CR25]\]India5.84Per patientUS (2009)\$7.05Per patientScreening single laser photocoagulation treatment at a hospital \[[@CR25]\]India7.51Per patientUS (2009)\$9.07Per patientScreening Using Telescreening in rural areas \[[@CR25]\]India7.36Per patientUS (2009)\$8.88Per patientEnd-Stage Renal DiseaseDialysis \[[@CR29]\]China56,584.00Per yearUS (2004)\$94,356.62Per patient per yearDialysis \[[@CR29]\]Malaysia19,054.00Per yearUS (2004)\$28,871.91Per patient per yearDialysis \[[@CR29]\]Thailand31,651.00Per yearUS (2004)\$52,903.20Per patient per year1 session of hemodialysis in a hospital \[[@CR27]\]Jordan72.00Per sessionUS (2010)\$78.76Per sessionHemodialysis maintenance session in a hospital \[[@CR26]\]Iran, Islamic Rep.52.60Per sessionUS (2007)\$96.66Per sessionHemodialysis in a hospital \[[@CR28]\]Sudan15,747.68Per patient per yearSudan (2009)\$8,374.01Per patient per yearHemodialysis in a hospital \[[@CR28]\]Sudan146.58Per patient per sessionSudan (2009)\$77.95Per patient per sessionRenal Transplant (first year expenses) \[[@CR29]\]China54,886.00Per yearUS (2004)\$91,525.12Per patient per yearMaintenance post index year of transplant patient \[[@CR29]\]China27,259.00Per yearUS (2004)\$45,455.73Per patient per yearRenal Transplant (first year expenses) \[[@CR29]\]Malaysia70,022.00Per yearUS (2004)\$106,102.06Per patient per yearMaintenance post index year of transplant patient \[[@CR29]\]Malaysia14,111.00Per yearUS (2004)\$21,381.94Per patient per yearRenal Transplant (first year expenses) \[[@CR29]\]Thailand45,953.00Per yearUS (2004)\$76,808.34Per patient per yearMaintenance post index year of transplant patient \[[@CR29]\]Thailand19,349.00Per yearUS (2004)\$32,340.97Per patient per yearKidney transplantation, including operation and following year \[[@CR28]\]Sudan34,097.85Per patientSudan (2009)\$18,131.93Per patientKidney transplantation, after the first year \[[@CR28]\]Sudan24,499.00Per patientSudan (2009)\$13,027.63Per patientTransplantation Procedure \[[@CR30]\]Iran, Islamic Rep.2,048.00Per patientUS (2005)\$4,769.20Per patientTotal cost (Transplant procedure, 1 year immunosuppression, donor costs) \[[@CR30]\]Iran, Islamic Rep.9,224.00Per patientUS (2005)\$21,480.05Per patientDefinitions: Per capita costs were divided by the population of the study country in 2012 as defined by the World Bank. Primary prevention defined as actions to reduce the probability of initial occurrence of disease. Secondary prevention defined as actions following the occurrence of disease to prevent either the recurrence of the same event or to reduce the risk of a different but related event*Abbreviations*: *CABG* Coronary Artery Bypass Grafting, *CHD* Coronary Heart Disease, *LOS* Length of Stay, *ICU* Intensive Care Unit

Discussion {#Sec8}
==========

Treating CVD and its risk conditions is complex, due in part to the interrelationship between hypertension, diabetes, and ischemic heart disease, and the fact that multiple shared risk factors affect CVD health outcomes. The clinical heterogeneity of CVD can make treatment costs for a single condition much more variable than in the case of infectious diseases or some other chronic diseases; these factors also affect the mean and distribution of costs within and across similar conditions. For instance, CVD encompasses different types of heart and related diseases, such as hypertension, stroke, and heart failure, with different levels of severity, and associated care and management. There are numerous clinical protocols for treating complicated conditions, and treatment includes different combinations of drugs, diagnostics and imaging technologies, surgery and different requirements for inpatient care and follow-up visits, making comparisons between studies all but impossible. Additionally, there are large variations in clinical characteristics, capabilities, and practices among and within countries; it is possible to have a wide distribution of costs even within a hospital if they offer various levels of care, such as general, specialty, and intensive care wards \[[@CR31]\].

Another factor affecting the variation in costs was differences in methodology used across studies. There was a lack of standard reporting across the studies, most notably failure to describe cost ingredients. When studies disaggregated costs, there were not clear and common categories for input or activity cost categories. In addition, for disaggregated input costs, it was unclear when activities included personnel in the costs. Many studies provided costs for imaging, diagnostic or therapeutic services, without indicating whether personnel costs were included. Surgery was a common category, but descriptions of what resources comprised surgery or surgical procedures were absent from the majority of the studies. Cost data was most informative when disaggregated into categories and inputs, allowing the reader to better understand heterogeneity and make more useful comparisons. We also noticed a lack of clinical protocol reporting in publications. Reporting on clinical protocols underlying the CVD interventions may help readers evaluate the comparability and transferability of costs estimates across studies, depending on the study objective.

Trends in the data emerged despite these limitations. It is clear that there is growing interest and concern about the prevalence and cost of treating cardiovascular and risk conditions at every national income level. BRICS countries and a few other populous Asian countries produced about three-quarters of the literature we identified, laying a foundation of evidence for the costs of treating CVRDs in LMICs. The current evidence confirms that is expensive to provide treatment for complicated or advanced cardiovascular conditions, with inpatient treatment for CVD easily costing upwards of \$10,000 per patient (Fig. [4](#Fig4){ref-type="fig"}). Looking at the distribution of costs by condition, managing risk conditions is generally much less expensive than treating acute CVD conditions (Fig. [5](#Fig5){ref-type="fig"}).Fig. 4Hospital Costs by Condition (USD 2012). Showing the average, minimum, and maximum costs of inpatient treatment for various cardiovascular and chronic kidney disease conditions. Source: extracted cost data for this reviewFig. 5Unit Cost Distributions. Figure of four overlapping histograms showing the distribution of identified costs per patient for four conditions: hypertension management, diabetes mellitus, stroke, and acute ischemic heart disease. These four conditions had the most robust data available in the review

Our review identified critical gaps in information and demonstrated the substantial heterogeneity in treatment costs for CVRD across the available data for LMIC countries. The most obvious gap was the need for more consistent methodology, with clear presentation of data on cost ingredients and drivers. Cost data are used to inform resource allocation and to improve efficiency; health policy makers thus need to understand the underlying causes of health expenditures in order to make informed decisions. We identified no longitudinal studies in LMICs, however several modeled studies looked at health costs over a longer period of time. We anticipate that longitudinal studies would be particularly revealing regarding costs of chronic conditions, such as hypertension and diabetes, which require lifelong management. In the absence of longitudinal studies, health decision-makers are currently allocating CVD resources with an incomplete picture of future costs.

We found very few cost analyses of CVD conditions conducted in low-income countries. While these countries are likely the most heavily resource-constrained, they are also likely the least prepared to prevent and treat CVD conditions. We found no data on the cost of diabetes care in low-income countries. Middle-income countries, particularly upper-middle income countries such as Brazil, China, and South Africa, have produced research or publications regarding technologically complex interventions, revealing relatively higher health system capacity. As the double-burden of infectious and chronic conditions increases, and policy makers in low-income countries expand health resources for chronic conditions, published studies from other LMICs can provide economic evidence on CVD interventions.

Because our analysis focused on the unit costs of clinical interventions, we did not include many of the WHO Best Buys for NCDs such as tobacco taxation and regulation, population salt regulation, or health and physical activity promotion. Population based prevention measures typically cost pennies per person, but the total cost to the government will depend on the population size. It was beyond the scope of this paper to compare the total costs of population based interventions with clinical prevention and treatment costs. The evidence in this review strongly suggests that costs quickly escalate with advanced CVRD treatment; future investment in population prevention of CVRDs could reduce the need for these expensive clinical interventions.

We also excluded studies presenting the cost of implementing guidelines for initiating prevention strategies of CVRDs based on absolute risk \[[@CR32], [@CR33]\]. While prevention is extremely important for averting premature death and the high costs of surgery and post-operative care, setting risk guideline thresholds is less associated with changes in unit costs than with changes in long-term cost-effectiveness and total budget impact. The economic evaluations we identified regarding risk guidelines ultimately fell outside of our purview due to their health outcome denominators.

Conclusion {#Sec9}
==========

The evidence for CVRD treatment and prevention costs in LMICs is limited, particularly in low-income countries. We recommend conducting economic studies alongside efforts to scale up treatment and preventions on CVRD in these settings. Initially standard methods of care or clinical protocol could be used to inform costs of CRVD treatment and prevention in order to estimate costs and their key drivers are across settings. There is also a need to estimate the actual resource use and costs in the provision of care, as such information can be used to improve efficiency and budgeting over time. In addition to following recommended costing analysis protocols \[[@CR15]\], future research on the costs of CVD prevention and care should disaggregate the cost inputs, especially long term costs, since most individuals with CVRD experience worsening disease severity and more sequelae over time.

The burden of CVRD in LMIC is already substantial and will continue to increase in the absence of concerted prevention efforts, which could contain costs by reducing future spending on CVD. At the same time, the prevalence of CVD is already very high in regions such as Latin America and South and East Asia. Hence, efforts to allocate NCD resources equitably will inevitably include a balance of both prevention and advanced treatments for existing cases of CVD. Ongoing efforts to understand the cost of delivering CVRD care in these regions will be critical to achieving universal health coverage and improving overall population health.
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CKD

:   Chronic Kidney Disease

CC

:   chagas cardiomyopathy

CVD

:   Cardiovascular disease

CVRD

:   Cardiovascular Disease and Risk Conditions

DALY

:   Disability-adjusted life-year

ESRD

:   End-stage renal disease

LYS

:   Life years saved

LCU
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LMIC

:   Low- and middle-income countries
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:   Non-communicable disease
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:   Quality-adjusted life-year

T2DM
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